Quantcast

Latest Uric acid Stories

2011-06-28 05:30:00

WASHINGTON and DEERFIELD, Ill., June 28, 2011 /PRNewswire/ -- Men's Health Network (MHN) and Takeda Pharmaceuticals North America, Inc., today announced a partnership to launch the "Gout Pit Stop," an educational campaign to raise awareness about gout, a type of arthritis that affects approximately 8.3 million people in the U.S. and is the most common form of inflammatory arthritis in men. Launched just before one of the biggest events of the year on the racing calendar and during Men's...

2011-05-26 14:05:33

A pan-European study of 755 gout patients found that prevalence of self-reported gout was highest in the UK (2.2%) and lowest in France (0.76%). French, German and British gout patients all had lower quality of life scores, and had significant work and social impairment compared to controls (p<0.05 for all comparisons). Interestingly, patients in these countries also had more hypertension, diabetes, congestive heart failure and renal disease (p=0.05) compared to healthy controls. Abstract...

2011-05-26 12:00:00

EAST BRUNSWICK, N.J., May 26, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Marketing Authorization Application (MAA), filed by its wholly owned subsidiary, Savient Pharma Ireland Limited, seeking approval of KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy, has completed validation by the European Medicines Agency (EMA). The MAA has been deemed valid by the EMA...

2011-05-25 15:45:00

LONDON, May 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, UK. Results from Primary Dosing Period and Ongoing Extension of Phase 2b Combination...

2011-05-19 07:30:00

HAYWARD, Calif., May 19, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout. This randomized, double-blind, placebo-controlled study will evaluate the safety and urate-lowering activity of 400 and...

2011-05-17 10:00:00

CLEVELAND, May 17, 2011 /PRNewswire/ -- A new survey from the nonprofit Gout & Uric Acid Education Society (GUAES) highlights an alarming awareness gap among Americans regarding the risk factors for gout, a chronic, potentially disabling form of arthritis which now affects an estimated 8.3 million Americans.(1) Among the survey findings are that only one in 10 Americans correctly cited cardiovascular disease as a risk factor for gout, while only one in three Americans correctly...

2011-05-04 17:23:00

EAST BRUNSWICK, N.J., May 4, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that it has, through its wholly owned subsidiary, Savient Pharma Ireland Limited, delivered via courier to the European Medicines Agency (EMA) and the assigned co-rapporteurs, the Marketing Authorization Application (MAA) for KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Currently there are no EMA...

2011-05-02 12:32:08

The incidence of gout is on the rise and duel energy CT has the potential to allow non-invasive diagnosis of the disease, according to radiologists at the University of British Columbia, Vancouver General Hospital, in Vancouver, BC. Gout is caused by the deposition of monosodium urate (MSU) monohydrate crystals that stimulate acute episodes of inflammation. Chronic tophaceous gout often presents as juxtarticular soft-tissue masses, distinct erosions, overhanging bony margins, and thickening...

2011-04-28 15:05:00

EAST BRUNSWICK, N.J., April 28, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that three abstracts will be presented at the European League Against Rheumatism (EULAR) 2011 Annual Congress. The conference will take place on May 25 - 28 in London, United Kingdom, and will feature the abstracts as two oral presentations and one poster presentation. The first scheduled oral presentation and the poster session will address the prevalence of gout in Europe...

2011-04-25 08:00:00

SAN DIEGO, April 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that additional data from its completed Phase 2b study (Study 203) evaluating lesinurad in combination with allopurinol in gout patients not adequately responding to allopurinol alone will be presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) on May 26, 2011 in London, UK. The Company will also present additional data from a...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related